Update on selected markers used in risk assessment for vascular disease.
CVD remains the greatest health risk in the U.S.. Assessment of laboratory data in establishing risk and treatment modalities has come to the forefront in patient primary care. Guidelines published in the ATP III document by the NCEP have incorporated lower limits of lipids and included a number of risk factors and conditions, such as the metabolic syndrome associated with insulin-resistance, as a means for earlier detection and intervention in CVD. Endothelial dysfunction and the associated inflammatory process, including soluble plasma markers, have lead to the addition of hs-CRP as an adjunct to other laboratory indicators of CVD. The precise mechanisms and interrelationships between these factors and atherosclerosis have yielded some confusing data, along with investigations of a number of associated substances and conditions. An emerging theme is the body's response to injury and stress; a lack of metabolic balance. While currently outside the domain of routine laboratory testing, future CVD risk assessment may include the metabolic by-products generated by chronic external pressures, including genetic predisposition or alterations associated with socioeconomic factors. Further studies are needed to better understand the significance each plays in assessing the individual's development and CVD risk.
Carreiro-Lewandowski
Eileen
E
Department of Medical Laboratory Science, University of Massachusetts Dartmouth, N Dartmouth, MA 02747-2300, USA. ecarreiro@umassd.edu
D015415:Biomarkers / Q000032:analysis*; D003327:Coronary Disease / Q000175:diagnosis*; D004727:Endothelium / Q000473:pathology / Q000502:physiology; D006801:Humans; D006949:Hyperlipidemias / Q000175:diagnosis*; D007249:Inflammation; D008055:Lipids / Q000097:blood; D018570:Risk Assessment
D015415:Biomarkers; D008055:Lipids